Trial patients
leukopenia, carcinoma peritonei, fibrous, colon primary tumors, adenocarcinoma, GM-CSF, postoperative laryngospasm, deaths, LAMN
RECURRENCE, LEUKOPENIA, MINOR, DISEASE, ADENOCARCINOMA, PRIMARY TUMOR, EVENTS, DISEASE, URINARY TRACT INFECTION, MUCINOUS ADENOCARCINOMA
A total of 18 patients were enrolled and treated with laparoscopic CRS/HIPEC. The median age was 57 years and 39% of patients were female. The primary tumor site was the appendix in 15 cases and the colon in 3. Of the appendiceal primary patients, 8 had LAMN, 2 had mucinous adenocarcinoma, and 5 had poorly differentiated adenocarcinoma with signet ring cells. The 3 patients with colon primary tumors had moderately differentiated adenocarcinoma. Four of the 10 patients (40%) with adenocarcinoma histology had systemic chemotherapy prior to surgery, and 3 (30%) received adjuvant systemic therapy. Three patients refused systemic treatment. At the time of CRS/HIPEC, 9 patients had residual adenocarcinoma, 2 had persistent LAMN, 1 had persistent low-grade carcinoma peritonei, and 6 had only fibrous tissue or acellular mucin remaining. The median PCI was 3 (range 0–10). The median operative time was 219 min (range 134–378) and median EBL was 10 mL (range 0–100). The most common procedures performed were omentectomy (Baseline, operative, and postoperative variables of 18 patients who underwent laparoscopic CRS/HIPEC on a prospective clinical trialThe median time to return to bowel function was 3 days (range 1–7), intravenous narcotic use was 3 (range 1–8), and length of stay was 6 (range 3–11). Three patients (17%) experienced 30-day morbidity, all of which were minor (one patient had urinary tract infection, one had leukopenia requiring GM-CSF, and one had postoperative laryngospasm requiring temporary BIPAP). There was no major morbidity or postoperative mortality. The median follow-up for trial patients was 48.0 months (95% CI 33.4, 57.3). During the follow up time, 4 patients experienced recurrence at 5.2, 8.0, 9.4 and 46.0 months, all of whom had adenocarcinoma histology. Three of these 4 patients died of disease. There were no recurrence events or deaths in the patients with LAMN (Fig. Disease free (